Clinical trials: Pharmakokinetic
Sickle Cell Disease (SCD)
Optimizing Hydroxyurea Dosage With Pharmakokinetic in Patients Suffering of Moderate to Severe Sickle Cell Anemia
The goal of this study is to evaluate if patients with sickle cell disease can achieve a maximum tolerate dose of hydroxuyrea (HU) over a period of 12 months faster with pharmacokinetic testing than the standard of care bloodwork…
- Trial name
- OPTIMA (NCT06761560)
- Testing
- Pharmacokinetic based dosage change, Pharmacokinetic dosing
- Where
- Canada
- Volunteers
- 29 people
- Sponsor
- Yves Pastore